Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine

Abstract

The management of osteosarcoma (OS) patients presents a significant clinical challenge. Despite progress in conventional and targeted therapies, the survival rate of OS patients remains limited largely due to therapy resistance and the high metastatic potential of the disease. OS models that accurately reflect the fundamental characteristics are vital to the innovation and validation of effective therapies. This review provides an insight into the advances and challenges in OS drug development, focusing on various preclinical models, including cell lines, 3D culture models, murine models, and canine models. The relevance, strengths, and limitations of each model in OS research are explored. In particular, we highlight a range of potential therapeutics identified through these models. These instances of successful drug development represent promising pathways for personalized OS treatment.

Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K/AKT pathway

“…Osteosarcoma is a primary malignant bone tumour that poses a significant clinical challenge (Tan et al, 2023). Over the last two decades, the incidence of malignant bone tumours, especially osteosarcoma, has increased (Xu et al, 2023).…”